share_log

BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities

BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities

BioCryst Pharmicals更新了与Torii Pharmacetica在日本的ORLADEYO协议;BioCryst Japan K.K. 负责所有商业促销活动,Torii 将负责遗传性血管性水肿疾病宣传活动
Benzinga ·  2023/11/30 09:11

BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities

BioCryst Pharmicals更新了与Torii Pharmacetica在日本的ORLADEYO协议;BioCryst Japan K.K. 负责所有商业促销活动,Torii 将负责遗传性血管性水肿疾病宣传活动

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发